Drug development is a multifaceted journey characterized by meticulous research, rigorous testing, and regulatory scrutiny, aiming to bring novel therapeutics to the market to address unmet medical needs and improve patient outcomes. It begins with the identification of a potential target, often a molecule or biological pathway implicated in a disease process, through intensive scientific investigation and analysis of disease mechanisms. This initial stage involves a comprehensive understanding of the pathophysiology and molecular pathways involved, often aided by advanced technologies such as genomics, proteomics, and bioinformatics. Once a target is identified, researchers embark on the arduous task of discovering and designing compounds that can modulate or interact with the target to exert a therapeutic effect.
The process of drug discovery involves various approaches, including screening large libraries of chemical compounds, rational drug design based on structural biology and computational modeling, and leveraging natural products or existing drugs as starting points for optimization. Through iterative cycles of synthesis, testing, and optimization, researchers strive to identify lead compounds with desirable pharmacological properties, such as potency, selectivity, and safety profiles. These lead compounds undergo extensive preclinical evaluation, including in vitro studies and animal models, to assess their efficacy, safety, and pharmacokinetic properties.
Successful lead compounds advance to the clinical development phase, where they undergo rigorous evaluation in human subjects through a series of clinical trials designed to assess safety, efficacy, and optimal dosing regimens. Clinical trials are conducted in multiple phases, starting with Phase I trials focused on safety and pharmacokinetics in healthy volunteers, followed by Phase II trials to evaluate efficacy and dosing in a small cohort of patients with the target disease. Phase III trials involve large-scale studies to confirm efficacy, monitor long-term safety, and establish the benefit-risk profile compared to existing treatments or placebo.
Title : Rational design of battery cathode materials
Kyeongjae Cho, University of Texas at Dallas, United States
Title : Pharmaceutical chemistry studies of novel biologics and drugs for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Theoretical modeling in organic nanophotonics: Processes and devices
Alexander Bagaturyants, Retired, Israel
Title : Hot atom chemistry - Past, present and future
Shree Niwas Chaturvedi, Centre for Aptitude Analysis and Talent Search, India
Title : Chemical engineering of vanadium, titanium or chromium zeolites for application in environmental catalysis
Stanislaw Dzwigaj, Sorbonne Université, France
Title : Distal functionalization via transition metal catalysis
Haibo Ge, Texas Tech University, United States